Who are Clopidogrel active metabolite's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clopidogrel reloading, OAC + clopicogrel, bivalirudin + clopidogrel + aspirin, Clopidogrel, cilostazol, prasugrel/bivalirudin, Crushed ticagrelor, morphine,metoclopramide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clopidogrel-active-metabolite.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Clopidogrel active metabolite — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clopidogrel active metabolite (Clopidogrel active metabolite) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Antiplatelet agent. Area: Cardiovascular.

marketed P2Y12 receptor antagonist / Antiplatelet agent P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Clopidogrel active metabolite (Clopidogrel active metabolite) — University of Florida. Clopidogrel active metabolite irreversibly inhibits platelet P2Y12 adenosine diphosphate receptors, preventing platelet aggregation and thrombus formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Clopidogrel active metabolite TARGET	Clopidogrel active metabolite	University of Florida	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Clopidogrel reloading	Clopidogrel reloading	University of Pecs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
prasugrel/bivalirudin	prasugrel/bivalirudin	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	marketed	Antiplatelet agent + Direct thrombin inhibitor combination	P2Y12 receptor (prasugrel); Thrombin (bivalirudin)
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Antiplatelet agent class)

Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
Jeil Pharmaceutical Co., Ltd. · 1 drug in this class
University of Florida · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopidogrel active metabolite — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-active-metabolite. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing